Saturday, July 11, 2026

Drug profile · INN

rhtnk-tpa

rhtnk-tpa is a tissue-type plasminogen activator exogenous protein.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — rhtnk-tpa
Class
Route
Patents
0
Programs
3
Data quality
0.70

Quick answer

rhtnk-tpa is a tissue-type plasminogen activator exogenous protein.

Key facts

INN rhtnk-tpa
Mechanism Tissue-type plasminogen activator exogenous protein
Target Tissue-type plasminogen activator

Mechanism of action

Tissue-type plasminogen activator exogenous protein

Primary target: Tissue-type plasminogen activator

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. TNK-tPA Phase 3 · First People's Hospital · Acute Ischemic Stroke
  2. [2025]372-001 Phase 3 · Chinese Academy of · Acute Ischemic Stroke
  3. TNK plus standard medical treatment Unknown · Chinese Academy of · Acute Ischemic Stroke

Related & competitor drugs

  1. alteplase Tissue-type plasminogen activator exogenous protein
  2. reteplase Blood and blood forming organs (B01)
  3. tenecteplase Blood and blood forming organs (B01)
  4. rt-pa Tissue-type plasminogen activator exogenous protein

Frequently asked questions

What is rhtnk-tpa?

rhtnk-tpa is a tissue-type plasminogen activator exogenous protein.